Company profile: Lakewood-Amedex
1.1 - Company Overview
Company description
- Provider of novel anti-infective therapeutics for serious infectious diseases, including Bisphosphocins, a novel class of antimicrobial agents effective against a wide range of bacteria and fungi, including antibiotic-resistant strains; and Nu-3 gel, a Bisphosphocin gel for treating infected diabetic foot ulcers, advancing into Phase 2 clinical trials.
Products and services
- Nu-3 gel: A clinical-stage gel formulation of Bisphosphocin for treating infected diabetic foot ulcers, currently advancing into Phase 2 clinical trials
- Bisphosphocins: A broad-spectrum, novel class of antimicrobial agents effective against a wide range of bacteria and fungi, including antibiotic-resistant strains
- Anti-infective product development: A novel-approach development service creating anti-infective products for the treatment of serious infectious diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lakewood-Amedex
C3J Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage bacteriophage therapeutics and a synthetic phage platform to engineer phages for multidrug-resistant infections, including AP-PA02 for Pseudomonas aeruginosa respiratory disease in cystic fibrosis and non-CF bronchiectasis, AP-PA03 for acute pneumonia (hospital-acquired and ventilator-associated), and AP-SA02 for Staphylococcus aureus bacteremia and potential prosthetic joint infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C3J Therapeutics company profile →
BioCat
HQ: Germany
Website
- Description: Provider of specialized distribution of products and services to the life science research market, offering a wide portfolio of instruments and research reagents in genomics, proteomics, and cell biology for academia and the pharma and biotech industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioCat company profile →
Identigen
HQ: Ireland
Website
- Description: Provider of DNA-based solutions to the agri-food industry, applying genetic identification to improve the quality, integrity and safety of the global food supply. Offers DNA TRACEBACK for verifying food origin and production practices, and DATALIVE for animal lifecycle insights to support sustainable business and environmental practices. Operates in Ireland, UK, EU, USA and Canada.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Identigen company profile →
BostonGene
HQ: United States
Website
- Description: Provider of AI-powered molecular and immune profiling and a cloud-based platform for personalized cancer therapy analysis; multiplex immunofluorescence (MxIF) pipeline analyzing tissue architecture and cell interactions, detecting up to 40 protein markers; bioinformatics services using multi-omics databases and proprietary software; biopharma solutions and target analysis to evaluate drug candidates in a certified environment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BostonGene company profile →
Ring Therapeutics
HQ: United States
Website
- Description: Provider of programmable genetic medicines enabled by AnelloScope (anellovirus discovery), AnelloScreen (tissue tropism, redosability, potency, immunogenicity), AnelloDesign (computational vector design), AnelloVector (non-integrating engineered viral nucleic acid delivery), AnelloLP (surface-payload viral particles for immune evasion), and AnelloBricks (scalable manufacturing for clinical and commercial production).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ring Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lakewood-Amedex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lakewood-Amedex
2.2 - Growth funds investing in similar companies to Lakewood-Amedex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lakewood-Amedex
4.2 - Public trading comparable groups for Lakewood-Amedex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →